Experts issue warning that Covid vaccine may trigger deadly brain inflammation - after man was struck down after just one jab
The unnamed 60-year-old sought help from medics in Paris, France after suddenly developing walking problems and mental confusion, four weeks after receiving a dose of AstraZeneca 's Covid jab.
Brain scans revealed he was suffering from meningoencephalitis—a life threatening swelling of the brain and the tissue surrounding the brain and spinal cord—according to doctors who shared his tale in a medical journal.
While the condition can be caused by health problems like an infection or blood cancers, analysis of the man's brain tissue showed no signs of any viruses or other disease that could be responsible
This led medics to believe that the man's swelling was caused by his Covid vaccination, specifically his immune system over-reacting to the jab.
They then diagnosed him with postvaccinal encephalitis, dangerous brain swelling following a jab.
The man, who suffered two bouts of brain swelling while in the care of the medical team, was treated with special drugs to suppress his immune system for six months until his symptoms were under control.
Doctors, who reported the case JAMA Neurology, said the man had made an almost full recovery three years after.
However, they noted he continued to suffer from ongoing mild problems with his attention span.
The patient originally showed significant improvement after being treated when he first suffered symptoms four weeks after getting the jab.
However, he returned with the same walking and mental confusion problems three months later which when medics conducted the brain biopsy and put him on six months of medication.
Medics said the relapse showed the importance of sustained drug treatments for such patients as well as 'prompt diagnosis and aggressive treatment'.
Encephalitis after Covid vaccines have been reported before.
A study published in 2023 on 65 patients found AstraZeneca was the most common vaccine brand linked to the reaction, accounting for over a third of cases.
The authors of that report highlighted that what exactly causes vaccine induced encephalitis to occur in some patients is not yet understood.
However, they added that majority of cases have made a full recovery.
While the team behind the most recent report did not specify when the man received the Covid jab it is likely to have been in 2021.
France—alongside many European countries—suspended and then restricted the use of the British designed jab in early 2021.
This followed reports of a small number of patients suffering an extremely rare but potentially deadly blood clotting reaction.
Called thrombosis with thrombocytopenia syndrome (TSS), this is a medical condition where a person suffers blood clots along with a low platelet count. Platelets typically help the blood to clot.
The complication—missed in initial safety trials due to its rarity but now listed as a potential side effect of the jab—has also previously been called vaccine-induced immune thrombotic thrombocytopenia (VITT).
Health officials first identified cases of VITT linked to AstraZeneca's jab in Europe as early as March 2021, just over two months after the vaccine was first deployed in the UK.
However, it wasn't until April that year that evidence became clear enough that the jab started to be restricted.
Officials first stopped dishing out the jab to people under the age of 30. They then expanded this to only people over 40 in May 2021.
As the vaccine still worked against Covid, it was still deemed worth giving to older Britons who were at greater risk of death or injury from falling ill with the virus.
About 50million doses of the AstraZeneca jab were dished out in the UK in total.
Official data shows at least 81 Brits have died from blood clot complications apparently linked to the AstraZeneca jab, according to figures collected by the UK's drug watchdog, the Medicines and Healthcare products Regulatory Agency.
A further unconfirmed number have been injured and/or disabled.
Further Covid vaccine rollouts have either minimised use of the AstraZeneca jab and/or phased it out entirely in favour of alternatives like those made by rival pharma giants Pfizer and Moderna.
With health officials not ordering any more doses, this effectively means the jab has all but been withdrawn in the UK.
While rare reactions to the jab has been linked to deaths and injuries, AstraZeneca's shot is credited with saving some 6million lives globally during the Covid pandemic.
The latest NHS figures show 293 Britons—or their families— have applied to a Government scheme to support the vaccine injured and had their claim the jab caused their health issues accepted.
However—under the rules of the widely criticised scheme—not all will receive the £120,000 compensation offered.
Survivors of jab injuries must be at least 60 per cent disabled by their injuries in order to qualify for a payout—for example losing a limb, a sense like your sight, or suffering complete paralysis.
The case of the French man comes amid growing concern about what has been dubbed 'post-vaccination syndrome'.
Linked to mRNA jabs, those made by the likes of Pfizer and Moderna but not AstraZeneca, the condition appears to cause brain fog, dizziness, tinnitus and exercise intolerance, the researchers reported.
Some sufferers also show distinct biological changes, including differences in immune cells and the presence of coronavirus proteins in their blood, years after taking the shot.
The condition is also said to increase the risk of reawakening a dormant virus called Epstein-Barr, which can cause flu-like symptoms, swollen lymph nodes and nerve issues.
The full results of the small study have not yet been published or peer reviewed, and the authors emphasised the results 'are still a work in progress.'
AstraZeneca's Covid jab timeline
January 2020: Oxford University scientists start working on a Covid vaccine after the World Health Organization declares the spread of the virus a 'Public Health Emergency of International Concern'
March 2020: Then Prime Minister Boris announced the first national lockdown. That same month, the Government invests £88million in the development of the Oxford vaccine
April 2020: Alongside AstraZeneca, scientists start the first clinical trials of their new vaccine. This involved 1,000 volunteers in the UK
July 2020: Results from phase two trials of AstraZeneca's jab are published
4 December 2020: Covid jab rollout begins with the Pfizer vaccine. Over-80s and care home workers are given priority
8 December 2020: Phase three trial results of the AstraZeneca's jab are published. These are what health officials will use to approve the jab for use in the UK
30 December 2020: AstraZeneca's jab is approved for emergency use
4 January 2021: First AstraZeneca doses start being dished out. Brian Pinker, 82, is the first person to receive the jab outside of clinical trials
8 January 2021: Frontline NHS staff start being offered vaccines
8 February 2021: Over-70s are called forward
14 February 2021: Roll-out opens up to Brits with underlying heath conditions, as well as the over-65s
28 February 2021: All over-60s are invited for jabs
11 March 2021: European countries start suspending use of the AstraZeneca jab after death of a 60-year-old woman from a blood clot
17 March 2021: Over 50s start being offered Covid jabs in the UK
19 March 2021: Several European countries reverse decision to suspend AstraZeneca jab after initial investigations find no link to reported blood clots
31 March 2021: People living with vulnerable adults are called forward to get a Covid vaccine in the UK, even if they are younger than eligible age groups
7 April 2021: UK restricts the use of the AstraZeneca vaccine to over-30s over a small but statistically significant risk of blood clots in younger people
30 April 2021: Over-40s are called forward for Covid jabs
7 May 2021: Restriction of the AstraZeneca vaccine is widened to include over-40s
August 2022: Government sources say they will not order anymore AstraZeneca Covid vaccines instead focuses on mRNA alternatives
March 2023: Dozens of patients and families launch legal action against AstraZeneca due to
April 2023: Widower of a BBC presenter Lisa Shaw who died after having the vaccine said he has 'no alternative' but to sue AstraZeneca
4 August 2023: Anish Tailor, whose wife Alpa died in March 2021 after receiving her first AstraZeneca dose, filed a product liability claim against AstraZeneca at London's High Court. His lawyer says he has nearly 50 other clients who will formally sue AstraZeneca in the coming months
17 August 2023: IT engineer Jamie Scott, who suffered a brain haemorrhage the day after his first AstraZeneca jab starts a legal case against the company. The law firm representing Mr Scott says it represents around 40 other individuals or bereaved families
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
15 minutes ago
- Daily Mail
Scientists discover cancer-fighting bacteria that 'soak up' forever chemicals in the body
A family of healthy bacteria may help 'soak up' toxic forever chemicals in the body, warding off their cancerous effects. Forever chemicals, also known as PFAS (per- and polyfluoroalkyl substances), are toxic chemicals that have been linked cancer, infertility and birth defects. They're named because they don't naturally break down in the environment or the body. Instead, they leech from plastic containers and nonstick cookware into food and build up in vital organs, increasing the risk of organ failure, infertility and some forms of cancer. Researchers at the University of Cambridge took samples of 38 strains of healthy bacteria living in the human gut and put them into lab mice. They found mice carrying human gut bacteria had up to 74 percent more 'forever' chemicals in their stool compared to mice without the bacteria within minutes of exposure. This suggests the toxins latched on to the bacteria as they moved through the digestive tract, leaving the body through the stool. While mountains of research have demonstrated deadly effects of forever chemicals, the new study is one of the first to show they can be taken out of the body instead of accumulating in there forever. And it builds on recent research showing a link between PFAS and the digestive tract. A study published last month, for example, found PFAS latches on to bile acids in the gut and eating fiber can help filter that excess bile out. Dr Kiran Patil, senior study author and toxicologist at the University of Cambridge, said: 'Given the scale of the problem of PFAS "forever chemicals," particularly their effects on human health, it's concerning that so little is being done about removing these from our bodies. 'We found that certain species of human gut bacteria have a remarkably high capacity to soak up PFAS from their environment at a range of concentrations, and store these in clumps inside their cells. 'Due to aggregation of PFAS in these clumps, the bacteria themselves seem protected from the toxic effects.' PFAS are thought to be endocrine-disrupting chemicals, meaning they imitate the body's hormones and interfere with the production of - and response to - natural hormones like estrogen and testosterone. This increases the risk of developing hormone-sensitive cancers like breast and ovarian cancer. The study, published Tuesday in the journal Nature Microbiology, looked at samples of 38 healthy bacteria in the gut. The researchers measured the effect of bacteria on levels of the forever chemicals perfluorononanoic acid (PFNA) and perfluorooctanoate acid (PFOA). PFOA is considered a Group 1 carcinogen by the International Agency for Research on Cancer (IARC), meaning it causes cancer in animals. PFNA, meanwhile, is a Group 2 carcinogen, suggesting it may cause cancer in animals. Over the course of 24 hours, nine of the tested bacteria reduced exposure to PFNA by 25 to 74 percent and PFOA levels by 23 to 58 percent. For both types of PFAS, Odoribacter splanchnicus lead to the greatest reductions. It's thought to produce the short-chain fatty acid butyrate, which boosts metabolism and immune function. The team believes PFAS latch onto the bacteria and are excreted out of the body through the stool. The researchers are now working on developing probiotic supplements to increase levels of these healthy bacteria in the gut. Dr Indra Roux, study co-author and researcher at the University of Cambridge's MRC Toxicology Unit, said: 'The reality is that PFAS are already in the environment and in our bodies, and we need to try and mitigate their impact on our health now. 'We haven't found a way to destroy PFAS, but our findings open the possibility of developing ways to get them out of our bodies where they do the most harm.'
Telegraph
an hour ago
- Telegraph
Philips Air Purifier 900 Series review: A small but powerful device for removing allergens and dust
What is the Philips PureProtect Mini 900 Series Air Purifier? The Philips Air Purifier 900 Series AC0920 is a compact model at approximately 36cm high by 22cm wide, suitable for spaces up to 65 square metres. This makes it an ideal air purifier for a bedroom or larger living space. At just £129.99 at the time of writing, it is excellent value, with filters costing only £34.99 annually. It's not the cheapest – some (like this Midea) retail for under £100 – but it's more affordable than premium brands like Dyson and Molekule. It is not a smart air purifier, so you can't connect it to your phone. But it is easy to operate and has a child lock, a colour changing light to indicate air quality and filter warning lights showing when it needs cleaning and replacing. It was extremely efficient at cleaning air in our real-world tests, earning the title of Best Value buy in our guide to the best air purifiers. JUMP TO: How we test air purifiers We independently test air purifiers in real homes, reflecting daily use. We set the device up from the box and run it for one hour on its medium or auto setting. We assess and score the following: Air quality testing: Using an air quality monitor, we measure the rate of small particulate matter (known as PM 2.5 and PM 10, referring to its size in microns), airborne chemicals called Volatile Organic Compounds (VOCs) and formaldehyde in the room before and after testing and record changes in the overall air quality indicator (AQI) score. Noise levels: We use a decibel monitor app to check the noise of the air purifier against ambient sound in the room. We record the loudest and the quietest settings. Value for money: We judge the initial cost, the price of replacement filters and how frequently they need replacing, as well as its energy use per kWh, measured using a smart plug. The Philips Air Purifier 900 Series was tested in a bedroom following the use of common aerosols, including deodorant and hair spray, as well as during everyday use in a living area. For more on at home air care, read our guides to the best fan, best dehumidifier and best humidifier. Why you can trust Telegraph Recommended Our thorough, real-world tests will always help you find the best product. No manufacturer ever sees Telegraph Recommended reviews before publication and we don't accept payment in exchange for favourable reviews, nor do we allow brands to pay for placement in our articles. All opinions are based on independent expert opinion and our hands-on testing. Visit our Who We Are page to learn more. Air quality Score: 9/10 In our tests, the Philips 900 Series performed better at improving air quality than some models more than twice the price. In just an hour, it reduced levels of PM 2.5 particles (small pollutants like dust and soot which can trigger allergies) in a large bedroom by 98 per cent. During the tests, the overall AQI score for the room improved by 96 per cent, dropping from an unhealthy 156 to just six (anything below 30 is good). It is also easy to tell what the current air quality is, since the air purifier has a coloured indicator light and a digital display on the top, showing PM 2.5 levels. But it doesn't tackle chemicals in the air like some others can, meaning it did not reduce levels of formaldehyde or VOCs. Ease of use The Philips 900 Series is easy to use with simple set-up instructions, although you must turn it upside down to remove the filter's protective cover before first use. After that it's self-explanatory, with straightforward controls to switch between its four modes: auto, fan speed one, fan speed two and night mode. A button dims the lights, which you can also hold to turn on the child lock. It beeps loudly so you know you've pressed the right button. We liked the warning light showing when the filter needs cleaning with a vacuum, as this could help extend its life. If cleaned regularly, the £34.99 filters last up to a year. Confusingly, although there is an on-box QR code for downloading the Philips app, this air purifier is not Wi-Fi-enabled and does not connect to it, so it can't be controlled remotely. Design As one of the best Philips air purifiers, this model is small but feels sturdy and durable. The HEPA filter, which can capture airborne particles like pollen and mould, is particularly robust and seems to be of a higher build quality than many other air purifiers with a HEPA filter for allergies. The display is clear to read, with the PM 2.5 levels shown as a number and as a light that changes colour to reflect their presence in the air (from a positive blue through to red for bad). This can be turned off for night time while a child-lock option is ideal for stopping tiny fingers from changing the settings. Controls are accessibly positioned, but frustratingly, you can't turn off the buttons' loud beeping noise. While helpful during the day, at night this is the one downside about the overall design. Operating noise Score: 7/10 The Philips 900 Series device was one of the quieter models we tested, running at just 30 dB on the quietest night mode setting (compared to an ambient sound in the home of 28 dB), making it a quiet air purifier for bedrooms. With the fan on top speed, noise was 62 dB, which is comparable with other air purifiers, including our Best Buy the Blueair Blue Max 3250i. We deducted a couple of points here because of the aforementioned loud beeps, which sound whenever you press any button on the device. This is intrusive if you are quietly trying to change the settings at night. Value Score: 9/10 At just £130, this air purifier performed significantly better than other budget options and pricier models. The filters are also reasonably priced, at £34.99 each, and this is made even more wallet-friendly by the fact they need replacing as infrequently as once a year. Many other air purifiers require a filter change at least every six months. In an hour, the Philips 900 Series used 0.007 kWh of energy, according to our tests, which works out as around 5p for every 24 hours of continuous use. Overall, this was a high-quality air purifier at a reasonable price, with low running costs too. Technical specifications We compared the Philips 900 Series with the premium Dyson Cool PC1 Air Purifier on performance, noise and value. Should you buy the Philips Air Purifier 900 Series? For clean air at a budget-friendly price, the Philips 900 Series performs even better than some larger, more expensive air purifiers. But this is a simple model, so you won't be able to track air quality or control the device remotely using an app. Yes, if: You want an efficient, compact air purifier You're looking for an air purifier with an air quality sensor You need a budget device with low running costs You want an air purifier with an auto mode No, if: You want Wi-Fi-connectivity or smart features You need a device that operates silently Philips Air Purifier 900 Series FAQs What size room is the Philips 900 Series suitable for? Up to 65 sq metres. Is it good for allergens and pollutants? Yes. It effectively removes PM 2.5 particles – those measuring 2.5 microns across – which can trigger allergies, and significantly improved air quality in our tests. How does the air quality sensor work? The sensor assesses the amount of PM 2.5 particles in the air passing through the device. It displays the level as a number, as well as showing a colour-coded light for air quality, from blue (good), through purple and pink to red (unhealthy). Is the Philips 900 Series noisy at night? No, the night mode is quiet at 30 dB – just over ambient noise (28 dB in our tests). But it beeps if you change any of the settings. Can I control the Philips 900 Series with my phone? No, there is no app control with this model. How often should I replace the filter in the Philips 900 Series? At least once a year. The device will let you know when it needs changing.
The Independent
an hour ago
- The Independent
How common cough syrup could help Parkinson's patients
A new study suggests that Ambroxol, a common cough syrup, may slow the progression of dementia in patients with Parkinson's disease. The year-long clinical trial involving 55 participants found Ambroxol to be safe, well-tolerated, and capable of reaching therapeutic levels in the brain. Participants receiving Ambroxol showed stable neuropsychiatric symptoms, unlike the placebo group, where symptoms worsened, and those with high-risk genetic variants showed improved cognitive performance. The drug appears to protect the brain from deterioration, as indicated by stable levels of the brain damage marker GFAP in the Ambroxol group compared to an increase in the placebo group. While Ambroxol is widely used in Europe for respiratory conditions, it remains unapproved for any use in the United States or Canada, with researchers hoping for larger trials to confirm its effectiveness.
